Zydus Lifesciences wins USFDA nod for diabetes drug Zituvimet Ruchika Sharma6 Nov 2023 11:34 AM ISTThe approval of ZITUVIMET is based on research, development, regulatory, and manufacturing work performed by Zydus teams.
Indian pharmaceutical market registers 9 percent growth in September: IQVIA Report Susmita Roy3 Nov 2023 5:43 PM ISTNew Delhi: The Indian Pharmaceutical Market (IPM) has witnessed a spike of nine percent in September 2023, according to International Quality and...
Zydus Lifesciences bags USFDA approval for type 2 diabetes mellitus drug Zituvio for adults Ruchika Sharma21 Oct 2023 11:19 AM ISTAhmedabad: Zydus Lifesciences Limited has announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA)...
Dr Reddy's Gets CDSCO Panel Nod to Study Antidiabetic FDC Empagliflozin, Sitagliptin, Metformin tablet Dr. Divya Colin20 Oct 2023 6:00 PM ISTNew Delhi: The drug major Dr Reddy's Laboratories has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard...
Sun Pharma Gets CDSCO Panel Nod To Market Sitagliptin, Metformin, Glimepiride FDC in Lower Strength Dr. Divya Colin30 Sept 2023 6:00 PM ISTNew Delhi: Pharmaceutical major Sun Pharma has got a go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard...
Synokem Gets CDSCO Panel Nod to Study Antidiabetic FDC Drug Sitagliptin plus Empagliflozin Dr. Divya Colin3 Sept 2023 6:00 PM ISTNew Delhi: The drug major Synokem Pharmaceuticals has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard...
Sun Pharma Gets CDSCO panel Nod To Manufacture, Market Sitagliptin, Metformin, Glimepiride antidiabetic FDC Dr. Divya Colin1 Sept 2023 6:00 PM ISTNew Delhi: Based on the Phase III clinical trial report and bioequivalence (BE) study report of the antidiabetic fixed-dose combination (FDC) drug...
Dapagliflozin suitable adjunct therapy to improve body composition in patients with type 2 diabetes Medha Baranwal17 Aug 2023 11:30 AM ISTSouth Korea: A recent study compared the therapeutic safety and efficacy of dapagliflozin, sitagliptin, or lobeglitazone adjunct therapy in type 2...
Akums gets approval for triple combination diabetes treatment Ruchika Sharma27 July 2023 4:50 PM ISTDelhi: Akums Drugs and Pharmaceuticals Limited has secured approval for its triple combination diabetes treatment. Sitagliptin 100, Pioglitazone 15...
Akums Pharma Gets CDSCO Panel Nod To Manufacture, Market Antidiabetic FDC Drug Dr. Divya Colin9 July 2023 6:00 PM ISTNew Delhi: Noting that the antidiabetic fixed-dose combination (FDC), Sitagliptin Phosphate Monohydrate 100mg/100mg plus Pioglitazone 15mg/15mg plus...
Novel triple-drug FDC superior to dual combination in type 2 diabetes patients poorly controlled with metformin Medha Baranwal2 Jun 2023 11:30 AM ISTIndia: A recent study has shown a triple-drug fixed-dose combination (FDC) of sitagliptin + dapagliflozin + metformin ER to be superior to dual...
Justify rationality for FDC Sitagliptin, Lobeglitazon: CDSCO Panel Tells Synokem Pharma Dr. Divya Colin21 May 2023 5:45 PM ISTNew Delhi: In line with the drug major Synokem pharmaceutical's proposal for deliberation of bioequivalence (BE) and phase III clinical trial protocol...
